SCHEDULE: Rosalind Advisors Updates MediWound Stake to 7%

Rosalind Advisors and related entities have updated their beneficial ownership in MediWound Ltd. to 7.0% of common shares, including warrants subject to a blocker provision.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 912,319 common shares of MediWound Ltd.
• This aggregate amount represents 7.0% of MediWound's common stock, calculated based on 12,835,186 shares outstanding as of January 16, 2026.
• The reported ownership includes 749,054 shares of common stock and 163,265 shares issuable upon the exercise of warrants.
• A blocker provision exists for the warrants, preventing exercise to the extent that it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Due to this blocker, the actual beneficial ownership of Rosalind Master Fund L.P. is deemed to be 749,054 shares, representing approximately 5.84% of the common stock, excluding the warrants.
• Rosalind Advisors, Inc. acts as the investment advisor to Rosalind Master Fund L.P., and Steven Salamon and Gilad Aharon are portfolio managers of the Advisor.
• The reporting persons disclaim beneficial ownership of the shares, except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. The continued significant stake by Rosalind Advisors suggests ongoing confidence in MediWound, although the clarification regarding the warrant blocker slightly tempers the immediate impact of the reported 7% ownership.

Positives

• A significant institutional investor group maintains a substantial stake in MediWound Ltd., indicating continued interest in the company.

Negatives

• The beneficial ownership percentage of 7.0% includes warrants that are subject to a blocker provision, meaning the immediate, fully exercisable stake is lower at 5.84% (749,054 shares), which could be perceived as less direct control or influence than the headline percentage suggests.

Risks

• The existence of a blocker provision on warrants means that the full potential ownership from these instruments cannot be realized if it pushes the holder's stake above 9.99%, potentially limiting the investor's ability to increase their stake rapidly through warrant exercise.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding MediWound Ltd.'s future performance or operations.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment by an institutional investor or group, signifying that the holder does not intend to influence or change control of the issuer. A 7% stake, even with a blocker provision on warrants, represents a notable position in a company, often signaling confidence in its long-term prospects within the biotechnology or medical device sector, where MediWound operates.

Comparison to Industry Standards

• StockSavvy.ai observes that a 7% beneficial ownership stake is a significant position for an institutional investor in a small-to-mid cap biotechnology company like MediWound Ltd. While not an activist stake (which would typically be filed under Schedule 13D), it places Rosalind Advisors among the larger non-insider shareholders.
• Compared to typical institutional holdings, a 7% stake is substantial enough to warrant attention from other investors, as it suggests a thorough due diligence process by a professional investment firm.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may provide a degree of confidence to other shareholders, indicating that a professional investor sees value in MediWound.
• Management: Awareness of a large, passive institutional holder may influence management's strategic decisions, though the 13G filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing is a routine disclosure of beneficial ownership and does not contain new operational or financial performance data for MediWound Ltd. While the continued significant stake by Rosalind Advisors is a positive signal of investor confidence, it does not provide a basis for a change in investment recommendation. Investors should hold their positions and await further operational updates or financial results from MediWound to make more informed decisions.

Keywords

MediWound Ltd., Rosalind Advisors, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Institutional Investor, Equity Stake, SEC Filing